Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 2/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RHEB | Q15382 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6588786 | 0.90 | MEN1 (0.39) | PRKAG1PRKAA2PRKAB1ALDH1A1RHEB | |
| SCHEMBL5822839 | 0.87 | KMT2A (0.51) | PRKAG1PRKAA2PRKAB1ALDH1A1KMT2A | |
| SCHEMBL5820048 | 0.82 | PRKAG1 (0.44) | PRKAG1PRKAA2PRKAB1ALDH1A1RHEB | |
| SCHEMBL6338723 | 0.81 | ALDH1A1 (0.38) | PRKAG1PRKAA2PRKAB1ALDH1A1KMT2A | |
| SCHEMBL6346213 | 0.81 | KMT2A (0.41) | PRKAG1PRKAA2PRKAB1ALDH1A1KMT2A | |
| Trifluoroacetic Acid SCHEMBL6367442 | 0.78 | KMT2A (0.43) | PRKAG1PRKAA2PRKAB1ALDH1A1KMT2A | |
| SCHEMBL5817654 | 0.78 | KMT2A (0.42) | ALDH1A1KMT2AMEN1MAPTTDP1 | |
| SCHEMBL10333279 | 0.74 | ALDH1A1 (0.68) | PRKAG1PRKAA2PRKAB1ALDH1A1KMT2A | |
| SCHEMBL8382700 | 0.72 | KMT2A (0.51) | PRKAG1PRKAA2PRKAB1ALDH1A1KMT2A | |
| SCHEMBL6366772 | 0.72 | HRH4 (0.52) | ALDH1A1KMT2AMEN1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2005511760-A | — | — | 2005-04-28 | — | — | JP | claimed |
| US-20050075334-A1 | 8-(1H-Benzimidazol-2-ylsulfanyl)-4(1H)-quinolinone derivatives; jun N-terminal kinase inhibitors; Alzheimer*s, Parkinson*s, and Huntington*s disease; amyotrophic lateral sclerosis, antiepileptic agents; hemorrhage, seizures, traumatic brain injuries or haemorrhaging strokes | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | claimed |
| EP-1458712-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003051277-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| WO-2006104983-A1 | THERAPEUTIC METHODS FOR TYPE I DIABETES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20050075334-A1 | 8-(1H-Benzimidazol-2-ylsulfanyl)-4(1H)-quinolinone derivatives; jun N-terminal kinase inhibitors; Alzheimer*s, Parkinson*s, and Huntington*s disease; amyotrophic lateral sclerosis, antiepileptic agents; hemorrhage, seizures, traumatic brain injuries or haemorrhaging strokes | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | US | disclosed |
| EP-1458712-A2 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051277-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075334-A1 | 8-(1H-Benzimidazol-2-ylsulfanyl)-4(1H)-quinolinone derivatives; jun N-terminal kinase inhibitors; Alzheimer*s, Parkinson*s, and Huntington*s disease; amyotrophic lateral sclerosis, antiepileptic agents; hemorrhage, seizures, traumatic brain injuries or haemorrhaging strokes | PARK7, HYPK, BCL2A1 | PRKAG1 340/4885PRKAA2 485/4885PRKAB1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.